BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17393309)

  • 1. Failures in a proton pump inhibitor therapeutic substitution program: lessons learned.
    Lu M; Malladi V; Agha A; Abudayyeh S; Han C; Siepman N; Graham DY
    Dig Dis Sci; 2007 Oct; 52(10):2813-20. PubMed ID: 17393309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
    Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
    Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J; Dodd S; Durkin M; Sloan S
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.
    Kusano M; Shimoyama Y; Kawamura O; Maeda M; Kuribayashi S; Nagoshi A; Zai H; Moki F; Horikoshi T; Toki M; Sugimoto S; Mori M
    Dig Dis Sci; 2007 Jul; 52(7):1673-7. PubMed ID: 17385034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
    Maev IV; Balashova NN; Busarova GA
    Klin Med (Mosk); 2003; 81(9):54-9. PubMed ID: 14598594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole.
    Muro Y; Sugiura K; Nitta Y; Mitsuma T; Hoshino K; Usuda T; Hayashi K; Murase Y; Shimizu M; Matsuo H
    Clin Exp Rheumatol; 2009; 27(3 Suppl 54):15-21. PubMed ID: 19796556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
    Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
    J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
    Kivioja A; Linnosmaa I; Vehviläinen A; Vohlonen I
    Eur J Pharm Sci; 2004 Feb; 21(2-3):171-8. PubMed ID: 14757488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intragastric acidity during the first day following administration of low-dose proton pump inhibitors: a randomized crossover study.
    Hata S; Arai M; Maruoka D; Tanaka T; Matsumura T; Suzuki T; Nakagawa T; Katsuno T; Imazeki F; Yokosuka O
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):296-301. PubMed ID: 22959094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
    Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.
    Poe RH; Kallay MC
    Chest; 2003 Mar; 123(3):679-84. PubMed ID: 12628862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.
    Orenstein SR; Hassall E; Furmaga-Jablonska W; Atkinson S; Raanan M
    J Pediatr; 2009 Apr; 154(4):514-520.e4. PubMed ID: 19054529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors?
    Zhou Q; Yan XF; Pan WS; Zeng S
    World J Gastroenterol; 2008 Apr; 14(16):2617-9. PubMed ID: 18442220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
    Mullner K; Molnar B; Tulassay Z
    Orv Hetil; 2007 Mar; 148(12):543-51. PubMed ID: 17444020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole.
    Damiano A; Siddique R; Xu X; Johanson J; Sloan S
    Dig Dis Sci; 2003 Apr; 48(4):657-62. PubMed ID: 12741452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center.
    Coté GA; Ferreira MR; Rozenberg-Ben-Dror K; Howden CW
    Aliment Pharmacol Ther; 2007 Mar; 25(6):709-14. PubMed ID: 17311604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
    Lu B; Zhang L; Wang J; Wang B; Zou X; Fei G; Chen D; Wang X; Wu B; Zou D
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1722-1727. PubMed ID: 29575167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
    Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
    Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.
    Littner MR; Leung FW; Ballard ED; Huang B; Samra NK;
    Chest; 2005 Sep; 128(3):1128-35. PubMed ID: 16162697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.